Clinical value of serum trophoblast cell surface protein 2 (TROP2) antibody in non-small-cell lung cancer patients

Abstract

Objective: This study was to explore the clinical role of serum trophoblast cell surface protein 2 (TROP2) antibody in patients with non-small-cell lung cancer (NSCLC).

Materials and methods: We collected serum specimens from 117 NSCLC patients, 40 benign lung disease patients, and 60 healthy controls. TROP2 antibody concentrations were measured using enzyme-linked immunosorbent assay.

Results: Serum TROP2 antibody levels were higher in the NSCLC group compared to the control group (p < 0.001). TROP2 antibody, at a cutoff value of 9.8 U/ml, showed good diagnostic performance for NSCLC.

Conclusion: Measurement of TROP2 antibody might have diagnostic value for patients with NSCLC.

Keywords:

• Antibodies
• clinical value
• non-small cell lung cancer
• trophoblast cell surface protein 2

Disclosure statement

The authors declare that they have no competing interests.

Funding information

This study was supported by research grants from Zhejiang Provincial Natural Science Foundation of China (LY14H200001), Medicines Health Platform Key Project of Zhejiang Province (2013ZDA024), Medicines Health Platform Project of Zhejiang Province (2015DTA018).